Strata Skin Sciences

Strata Skin Sciences is an American medical-device company focused on technologies used by dermatologists in the examination and treatment of skin conditions. The company was formerly known as MELA Sciences, Inc., reflecting an earlier emphasis on melanoma-related diagnostic technology. Its portfolio has included both diagnostic and therapeutic devices, with products intended to provide clinicians with additional information during skin examinations or to deliver controlled treatments for dermatological diseases. The company's best-known therapeutic platform is XTRAC, a device that delivers monochromatic ultraviolet light. In clinical dermatology, XTRAC is used by trained professionals to treat conditions including psoriasis and vitiligo. The system is designed to direct treatment to affected areas rather than exposing the entire body to ultraviolet light, making it part of the targeted phototherapy segment of dermatology equipment. XTRAC has been a central commercial offering for Strata Skin Sciences and represents the company's treatment-oriented business. Strata Skin Sciences has also been associated with MelaFind, a non-invasive dermatology device intended to assist dermatologists during the evaluation of pigmented skin lesions. MelaFind was developed to provide additional information in the assessment of lesions that may require further clinical attention. The device does not replace a physician's examination or histopathological diagnosis; rather, it was positioned as an adjunctive tool within a dermatologist's workflow. The company obtained CE Mark approval for MelaFind after completing a conformity-assessment process, enabling the product to be marketed in the European Union. A major corporate turning point occurred in July 2015, when the company acquired PhotoMedex, Inc. The transaction expanded Strata's relationship with dermatology-focused medical devices and brought the XTRAC business into the company's portfolio. Following the acquisition, the company planned to move its headquarters from Irvington, New York, to Horsham, Pennsylvania, in Montgomery County. This transaction and relocation marked a shift from the company's earlier identity as MELA Sciences toward a broader dermatology-device platform. The company operates in the specialized medical-technology market rather than in consumer skincare. Its customers and users are primarily dermatologists, dermatology practices, and other clinical settings equipped to use prescription or professionally administered devices. Its commercial positioning combines diagnostic support for skin examinations with targeted, non-invasive treatment technologies. Available reference material does not establish a complete current product catalog, detailed ownership structure, current executive roster, financial profile, or current geographic sales breakdown; those fields are therefore left unreported.

Strata Skin Sciences developed from MELA Sciences, Inc., an American medical-device company whose earlier corporate identity was associated with melanoma examination and diagnostic-support technology. Rather than operating as a consumer skincare label, the business has focused on equipment used by trained dermatology professionals. Its products are intended either to supplement clinical evaluation of skin lesions or to deliver non-invasive treatment for selected dermatological conditions. One of the company's principal diagnostic-related products is MelaFind. The device was designed to provide dermatologists with additional information when examining pigmented skin lesions. Its role was adjunctive: it supported the clinician's assessment but did not replace physical examination, clinical judgment, or tissue diagnosis where biopsy was required. The company later secured CE Mark approval for MelaFind after completing the relevant conformity-assessment procedure. That approval allowed the product to be marketed in the European Union and represented an important regulatory step in the product's international commercialization. The company's therapeutic business became particularly associated with XTRAC. XTRAC is a medical device that delivers monochromatic ultraviolet light for professional dermatological treatment. It has been used for conditions such as psoriasis and vitiligo. The technology belongs to the targeted-phototherapy category, in which treatment is directed toward affected skin areas rather than delivered uniformly to the whole body. XTRAC therefore gave the company a commercially established treatment platform alongside its diagnostic-support activities. In July 2015, Strata Skin Sciences acquired PhotoMedex, Inc. The acquisition was a major corporate and portfolio event, bringing together businesses with dermatology-device operations and strengthening the company's position around XTRAC and related technologies. Around the same period, the company planned to relocate its headquarters from Irvington, New York, to Horsham, Pennsylvania, in Montgomery County. The transaction and relocation formed part of the company's transition from the MELA Sciences name to the Strata Skin Sciences identity. The resulting organization has been positioned as a specialized provider of professional dermatology equipment, combining skin-examination support with non-invasive treatment systems. Its market is shaped by medical-device regulation, physician adoption, reimbursement and practice economics, clinical evidence, and the need for trained operation. The available reference material identifies XTRAC and MelaFind as central products but does not provide a sufficiently complete record of later product launches, current executives, financial performance, present ownership, or a comprehensive chronology of regulatory and commercial events. Those details are not asserted here.

• 2015

  Acquisition of PhotoMedex

  [1]Strata Skin Sciencesen.wikipedia.org

  The company acquired PhotoMedex in July 2015, expanding its dermatology-device activities and strengthening the strategic importance of the XTRAC business.

• 2015

  Planned headquarters relocation

  [1]Strata Skin Sciencesen.wikipedia.org

  After the PhotoMedex transaction, the company planned to move its headquarters from Irvington, New York, to Horsham, Pennsylvania.

A specialist medical-device company serving dermatology professionals with non-invasive diagnostic-support and targeted phototherapy technologies.

• Targeted ultraviolet phototherapy device

  XTRAC

  XTRAC is a professional dermatology device that delivers monochromatic ultraviolet light to affected skin. It has been used to treat conditions including psoriasis and vitiligo. The system is intended for administration by trained dermatology professionals and represents Strata Skin Sciences' principal therapeutic platform. Its targeted approach places it within the dermatology phototherapy market, alongside the company's diagnostic-support activities.

• Dermatology diagnostic-support device

  MelaFind

  MelaFind is a non-invasive device designed to provide dermatologists with additional information during the examination of pigmented skin lesions, including lesions that may warrant further evaluation. It is an adjunct to professional clinical assessment rather than a substitute for a physician's judgment or definitive diagnostic procedures. The product received CE Mark approval following completion of a conformity-assessment process, permitting sale in the European Union.

• 2015

  Acquisition of PhotoMedexM&A

  Background

  The company was transitioning from the MELA Sciences identity toward a broader dermatology-device platform and sought to expand its commercial and therapeutic portfolio.

  Action taken

  Strata Skin Sciences acquired PhotoMedex in July 2015.

  Aftermath

  The transaction broadened the company's dermatology activities, with XTRAC becoming a central therapeutic offering. The company also planned to relocate its headquarters to Horsham, Pennsylvania.

  Source

1. 1Strata Skin Sciencesen.wikipedia.org